FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016064805> ?p ?o ?g. }

• W2016064805 abstract "Due to the recent development of several promising chemotherapeutic agents, such as S-1, irinotecan (CPT-11) and paclitaxel, response rates for advanced gastric cancer to chemotherapy have improved. Thus far, however, the efficacy and survival benefits of sequential chemotherapy using these agents have not been evaluated. An additional benefit of outpatient sequential chemotherapy, that is, without hospitalization, would be its contribution to the maintenance of patients' social activities. The aim of this study was to retrospectively evaluate sequential outpatient chemotherapy for advanced gastric cancer.Patients with metastatic/recurrent gastric cancer treated with sequential outpatient chemotherapy were analyzed retrospectively. The sequential treatment consisted of S1-based chemotherapy as first-line therapy, low-dose CPT-11/CDDP as second-line therapy and weekly paclitaxel administration as third-line therapy.A series of 32 patients was enrolled in this study. During the sequential chemotherapy, all patients were treated at the outpatient ward of Kyoto University Hospital without hospitalization. The overall response rate was 37.5% and the median survival time was 523 days (95% confidence interval: 323-723 days). The progression-free survival for the three therapies was 135 days for S-1, 148 days for low-dose CPT-11/CDDP and 57 days for paclitaxel. Grade 4 neutropenia was observed in 1 patient (3.1%), and there were no treatment-related deaths. Univariate analysis showed that factors with significant impact on survival were pathological type (intestinal vs. diffuse), clinical response (responder vs. non-responder) and prior chemotherapy. Factors with p values <0.1, including pathological type, clinical response, prior chemotherapy and age (>75 vs. < or =75 years), were evaluated by multivariate analysis, which disclosed that clinical response and patient age were significantly related to patient prognosis.In terms of survival and maintenance of social activities of patients, outpatient sequential chemotherapy appears to be both feasible and effective for advanced gastric cancer. Although prospective analysis of sequential chemotherapy is difficult because of its complex treatment protocol, clinical trials to assess the survival benefits of second-line chemotherapy for advanced gastric cancer are clearly warranted." @default.
• W2016064805 created "2016-06-24" @default.
• W2016064805 creator A5011456408 @default.
• W2016064805 creator A5023782741 @default.
• W2016064805 creator A5035537632 @default.
• W2016064805 creator A5035602517 @default.
• W2016064805 creator A5038862421 @default.
• W2016064805 creator A5044882193 @default.
• W2016064805 creator A5054704526 @default.
• W2016064805 creator A5058389409 @default.
• W2016064805 creator A5059656401 @default.
• W2016064805 creator A5072294943 @default.
• W2016064805 creator A5088441550 @default.
• W2016064805 date "2007-01-01" @default.
• W2016064805 modified "2023-09-25" @default.
• W2016064805 title "Retrospective Evaluation of Sequential Outpatient Chemotherapy for Advanced Gastric Cancer" @default.
• W2016064805 cites W1883602322 @default.
• W2016064805 cites W1944693814 @default.
• W2016064805 cites W1946819517 @default.
• W2016064805 cites W1971653050 @default.
• W2016064805 cites W1976651872 @default.
• W2016064805 cites W1992408996 @default.
• W2016064805 cites W2015038037 @default.
• W2016064805 cites W2018619890 @default.
• W2016064805 cites W2036332127 @default.
• W2016064805 cites W2040446578 @default.
• W2016064805 cites W2045995303 @default.
• W2016064805 cites W2059972525 @default.
• W2016064805 cites W2089042542 @default.
• W2016064805 cites W2102914024 @default.
• W2016064805 cites W2131463911 @default.
• W2016064805 cites W2157416388 @default.
• W2016064805 cites W2331031707 @default.
• W2016064805 cites W2528428498 @default.
• W2016064805 cites W4233611416 @default.
• W2016064805 cites W4255683556 @default.
• W2016064805 doi "https://doi.org/10.1159/000100865" @default.
• W2016064805 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17356271" @default.
• W2016064805 hasPublicationYear "2007" @default.
• W2016064805 type Work @default.
• W2016064805 sameAs 2016064805 @default.
• W2016064805 citedByCount "7" @default.
• W2016064805 countsByYear W20160648052012 @default.
• W2016064805 crossrefType "journal-article" @default.
• W2016064805 hasAuthorship W2016064805A5011456408 @default.
• W2016064805 hasAuthorship W2016064805A5023782741 @default.
• W2016064805 hasAuthorship W2016064805A5035537632 @default.
• W2016064805 hasAuthorship W2016064805A5035602517 @default.
• W2016064805 hasAuthorship W2016064805A5038862421 @default.
• W2016064805 hasAuthorship W2016064805A5044882193 @default.
• W2016064805 hasAuthorship W2016064805A5054704526 @default.
• W2016064805 hasAuthorship W2016064805A5058389409 @default.
• W2016064805 hasAuthorship W2016064805A5059656401 @default.
• W2016064805 hasAuthorship W2016064805A5072294943 @default.
• W2016064805 hasAuthorship W2016064805A5088441550 @default.
• W2016064805 hasConcept C121608353 @default.
• W2016064805 hasConcept C126322002 @default.
• W2016064805 hasConcept C143998085 @default.
• W2016064805 hasConcept C167135981 @default.
• W2016064805 hasConcept C23123220 @default.
• W2016064805 hasConcept C2776694085 @default.
• W2016064805 hasConcept C41008148 @default.
• W2016064805 hasConcept C61434518 @default.
• W2016064805 hasConcept C71924100 @default.
• W2016064805 hasConceptScore W2016064805C121608353 @default.
• W2016064805 hasConceptScore W2016064805C126322002 @default.
• W2016064805 hasConceptScore W2016064805C143998085 @default.
• W2016064805 hasConceptScore W2016064805C167135981 @default.
• W2016064805 hasConceptScore W2016064805C23123220 @default.
• W2016064805 hasConceptScore W2016064805C2776694085 @default.
• W2016064805 hasConceptScore W2016064805C41008148 @default.
• W2016064805 hasConceptScore W2016064805C61434518 @default.
• W2016064805 hasConceptScore W2016064805C71924100 @default.
• W2016064805 hasLocation W20160648051 @default.
• W2016064805 hasLocation W20160648052 @default.
• W2016064805 hasOpenAccess W2016064805 @default.
• W2016064805 hasPrimaryLocation W20160648051 @default.
• W2016064805 hasRelatedWork W141948796 @default.
• W2016064805 hasRelatedWork W1976626931 @default.
• W2016064805 hasRelatedWork W2098455424 @default.
• W2016064805 hasRelatedWork W2255857863 @default.
• W2016064805 hasRelatedWork W2411805909 @default.
• W2016064805 hasRelatedWork W2552247405 @default.
• W2016064805 hasRelatedWork W2797202303 @default.
• W2016064805 hasRelatedWork W3026139564 @default.
• W2016064805 hasRelatedWork W3160572483 @default.
• W2016064805 hasRelatedWork W58191675 @default.
• W2016064805 isParatext "false" @default.
• W2016064805 isRetracted "false" @default.
• W2016064805 magId "2016064805" @default.
• W2016064805 workType "article" @default.